GeneralBullishBlockonomi · Jun 226/10
📰
Definium Therapeutics (DFTX) Stock Soars 52% on Breakthrough Depression Trial Results
Definium Therapeutics (DFTX) stock surged 52% following positive Phase 3 trial results for its depression treatment DT120, which demonstrated significant efficacy in improving depression scores alongside a clean safety profile. The breakthrough outcome validates the company's therapeutic approach and signals potential commercial viability for the candidate drug.